Key facts
- It has raised $310.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($310.0M) in Oct 2020.
- LianBio has filed 2 Form Ds with the SEC since 2020, most recently Apr 2021 ($3.0M sold to 1 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for LianBio
Create free account
No card required
Funding rounds
1 roundsOct 2020Early Stage VC (Series A)$310.0M▮
About LianBio
- Industry
- Biotechnology
PA Mark — not yet priced
LianBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in LianBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on LianBio in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.